Clinical Trials on Peritoneal Dialysis Catheter Exit Site Infection in United Kingdom

Total 23 results

Johns Hopkins University

Recruiting

Study Examining the Effect of a Novel Cannulation Knife on User Satisfaction and Common Central Venous Catheter Insertion Complications (SCAD)

Central Venous Catheter Exit Site Infection

United States
University of Colorado, Denver
Children's Hospital Colorado

Recruiting

A New Securement Method for External Tunneled Central Venous Access Devices (CVAD)

Central Venous Catheter Related Bloodstream Infection | Central Venous Catheter Exit Site Infection

United States
University of California, San Diego

Terminated

Use of a Novel Catheter Lock Solution For Treatment of Hemodialysis Catheter Infections

Infection; Dialysis Catheter

United States
Imperial College Healthcare NHS Trust

Completed

Taurolidine in Haemodialysis Catheter Related Bacteraemia

Catheter-Related Infections | Renal Dialysis

United Kingdom
CloudCath

Completed

A Prospective Clinical Study of the CloudCath System During In-home Peritoneal Dialysis (CATCH)

Peritoneal Dialysis-associated Peritonitis

United States
Thomas Jefferson University

Completed

Vancomycin Pharmacokinetics in Patients on Peritoneal Dialysis

Peritoneal Dialysis-associated Peritonitis

United States
Croydon Health Services NHS Trust

Completed

Effect of Copper on the Healing of Obstetric Wounds (ECHO)

Surgical Site Infection | Wound Infection | Cesarean Section; Infection | Perineal Infection

United Kingdom
CloudCath

Recruiting

A Prospective Clinical Study to Assess the Clinical Utility of Turbidity in Patients Using In-Home Peritoneal Dialysis (ACT)

End Stage Renal Disease | Peritonitis | Peritoneal Dialysis-associated Peritonitis

United States
Brigham and Women's Hospital
Northeastern University

Completed

Patient Safety Learning Laboratory: Making Acute Care More Patient-Centered (PSLL)

Venous Thromboembolism | Patient Fall | Adverse Drug Event | Severe Hypoglycemia | Hospital Acquired Pressure Ulcer | Central Line-Associated Bloodstream Infection (CLABSI) | Catheter-Associated Infection | Opioid-Related Severe Adverse Drug Event | Severe Hospital Acquired Delerium | Rapid Response Related...

United States
University of North Carolina, Chapel Hill

Not yet recruiting

Early Patient Removal of Urinary Catheters After Urogynecologic Surgery (CARES2)

Urinary Retention Postoperative | Postoperative Urinary Tract Infection | Catheter Site Pain

United States
Genelux Corporation

Completed

GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Carcinomatosis

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditions

United States
University of Alabama at Birmingham
National Cancer Institute (NCI)

Completed

Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer Patients (Ad5Delta24RGD)

Ovarian Cancer | Primary Peritoneal Cancer

United States
Ludwig Institute for Cancer Research
Roswell Park Cancer Institute

Completed

Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
TILT Biotherapeutics Ltd.
Merck Sharp & Dohme LLC

Recruiting

Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Ovarian Cancer (PROTA)

Platinum-resistant Ovarian Cancer | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Refractory Fallopian Tube Carcinoma | Platinum-Refractory Primary Peritoneal Carcinoma | Platinum-refractory Ovarian Carcinoma | Platinum-Sensitive Ovarian... and other conditions

United States, Finland
John Stoddard Cancer Center at Iowa Methodist Medical...

Unknown

Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States
Celgene

Completed

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Carcinoma, Non-Small-Cell Lung | Urinary Bladder Neoplasms | Tumor Virus Infections | Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms | Carcinoma, Transitional Cell | Carcinoma, Pancreatic Ductal

Spain, United States, France, Netherlands
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer

Neutropenia | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Ovarian Carcinosarcoma | Stage IV Ovarian Cancer | Stage III Ovarian Cancer | Infectious Disorder

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditions

United States
Genelux Corporation
GOG Foundation

Recruiting

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Platinum-doublet + Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076)

Fallopian Tube Cancer | Platinum-resistant Ovarian Cancer | Platinum-refractory Ovarian Cancer | Primary Peritoneal Cancer | High-grade Serous Ovarian Cancer | Endometrioid Ovarian Cancer | Ovarian Clear Cell Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Recurrent Peritoneal Malignant Mesothelioma | Recurrent Pleural Malignant Mesothelioma | Vaginal Squamous Cell Carcinoma, Not Otherwise Specified | Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor | Recurrent Merkel Cell Carcinoma | Recurrent Nasopharynx Carcinoma | Appendix Adenocarcinoma and other conditions

United States
Medicenna Therapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)

Clear Cell Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Primary Peritoneal Cancer | Endometrial Carcinoma and other conditions

United States, Australia, Korea, Republic of, Canada

Clinical Trials on Peritoneal Dialysis Catheter Exit Site Infection in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations